Full-Time
HRIS & Compensation Analyst
Posted on 5/16/2026
Piper Sandler
1,001-5,000 employees
Investment banking and securities brokerage services
Compensation Overview
$85k - $105k/yr
Minneapolis, MN, USA
Hybrid
 People & HR (2) |
|---|
| , |
- Workday Advanced Compensation: Deep experience configuring merit processes, bonus plans, and eligibility rules is required.
- Payfactors (or similar market pricing tools): Experience managing market data, job matching, and system integration.
- Excel Mastery: You must be an Excel power user capable of managing large datasets, building complex formulas, and creating models from scratch.
- Experience with Workday Report Writer and EIBs is highly preferred.
- Lead the configuration, testing, and maintenance of Workday Advanced Compensation, including merit cycles, bonus plans, stock/equity administration, and grade profiles.
- Serve as the system administrator for Payfactors, ensuring seamless integration with Workday and accurate market data aging.
- Identify manual compensation processes and re-engineer them into automated workflows to reduce administrative burden and error rates.
- Troubleshoot system issues, manage EIB loads, and partner with IT/HRIS teams on system upgrades and releases.
- Manage the annual compensation planning cycle (merit, bonus, and equity) from a technical and operational standpoint.
- Conduct job evaluations and market pricing using Payfactors to ensure external competitiveness and internal equity.
- Audit compensation data regularly to ensure accuracy and compliance with FLSA, pay equity laws, and internal governance.
- Collaborate with HR Business Partners to provide data-driven insights regarding salary adjustments, promotions, and new hire offers.
- Build complex reports and dashboards in Workday to provide real-time compensation analytics to leadership.
- Utilize advanced Excel skills (VLOOKUP, XLOOKUP, Index/Match, Pivot Tables, Macros/VBA) to model compensation scenarios and validate system data before loading.
- Create dynamic templates for total rewards statements and offer letters.
Piper Sandler is a full-service investment bank and securities firm that helps clients raise and manage capital, execute mergers and acquisitions, and navigate financial markets. It offers investment banking, brokerage, asset management, and advisory services through a global network of offices. The company works by providing capital-raising advice, underwriting, and advisory work across the client lifecycle, supported by its research, trading, and wealth-management capabilities. What sets Piper Sandler apart is its long history (founded in 1895), its global reach across the U.S. and Europe and the Middle East, and its emphasis on a partnership-driven approach with deep sector expertise—paired with regulated, locally compliant operations in multiple jurisdictions. The firm’s goal is to help clients realize the Power of Partnership by delivering tailored financial solutions that support growth, strategic transactions, and long-term value creation.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Minneapolis, Minnesota
Founded
1895
Simplify's Take
What believers are saying
- Record healthcare revenues and top biopharma equity bookrunning support fee growth.
- Patrick McCormack strengthens biopharma M&A origination in San Francisco.
- Distressed debt and special asset expansion opens restructuring advisory mandates.
What critics are saying
- Healthcare underwriting depends on volatile biotech and medtech capital markets.
- Legacy litigation from variable rate demand notes creates recurring expense risk.
- Revenue concentration in investment banking amplifies earnings swings if deal flow slows.
What makes Piper Sandler unique
- No. 2 U.S. M&A advisor for announced deals under $2 billion.
- No. 1 bank M&A advisor by deal count for thirteen straight years.
- Capital-light investment bank with deep healthcare, banking, and municipal advisory franchises.
Help us improve and share your feedback! Did you find this helpful?
Your Connections
People at Piper Sandler who can refer or advise you
Benefits
Wellness Program
Company News
Piper Sandler has downgraded several enterprise software stocks as companies struggle to monetise artificial intelligence amid macroeconomic pressures. Germany's SAP was cut to "neutral" from "overweight", with its price target reduced to €170 from €220, citing slower-than-expected cloud conversions as chief information officers prioritise AI adoption over traditional ERP migrations. SAP's significant exposure to Europe, the Middle East and Africa — approximately 46% of fiscal 2025 revenue — leaves it vulnerable to regional economic pressures. Analysts noted the sector is undergoing a "SaaS to AI transition" on a compressed timeline, with meaningful AI revenue contributions expected to take time. Collaboration software firms Asana and Monday.com were also downgraded to "neutral", with price targets of $7 and $85 respectively, facing slowing seat expansion and moderating growth.
Crocs' former IR chief joins Helly Hansen as Head of Finance and Operations. April 9, 2026 Kontoor Brands Inc. (KTB) reports that Erinn Murphy, formerly at Crocs, will join the company in early May as VP and global head of Finance and Operations for Helly Hansen and corporate investor relations. As a member of Helly Hansen's leadership team, Murphy will take an international assignment in Oslo, Norway, overseeing KTB's corporate investor relations. Murphy joins Kontoor from Crocs Inc., where she served as senior vice president, Investor Relations and Corporate Strategy. Prior to that, Murphy served as managing director of Consumer Equity Capital Markets for Piper Sandler. She was recently appointed to the board of Revolve Group, Inc. Murphy's appointment coincides with an expanded role for Michael Karapetian, who will serve as vice president of Global Brand and Operations Finance and Corporate Investor Relations, with responsibility for Global Brand and Supply Chain Finance and corporate investor relations. Karapetian will return from his international assignment at Helly Hansen in the third quarter of 2026 to allow for a transition period. The hiring of Murphy was announced a day after Kontoor reported that Joseph Alkire, who, in addition to his responsibilities as chief financial officer and global head of operations, will assume global responsibilities for the Helly Hansen brand, effective immediately. Børre Hegbom will continue as SVP and Global Head of Helly Hansen. Formerly Helly Hansen's managing director of Sport, Hegbom was promoted to that role last October. Kontoor, which also owns Wrangler and Lee, acquired Helly Hansen in June 2025. Images courtesy Helly Hansen and Crocs, Inc.
Piper Sandler initiated coverage of Dime Community Bancshares, Inc. (NASDAQ:DCOM) with an Overweight rating and a $37 price target on 16 March. The firm expects continued recovery in net interest margin, supported by significant loan repricing over 2026 and 2027. During the Q4 2025 earnings call, CEO Stuart Lubow reported core earnings per share of $0.79, up 88% year-on-year, driven by record quarterly revenue of $124 million. Core deposits increased by $1.2 billion year-on-year, whilst business loans rose over $500 million compared to the prior year. Dime Community Bancshares operates through its subsidiary, Dime Community Bank, providing commercial and consumer banking services. The company is targeting an efficiency ratio below 50% for 2026.
Secretome Therapeutics announces participation in upcoming investor conferences. PLANO, Texas-(BUSINESS WIRE)-Secretome Therapeutics, a clinical-stage biotechnology company developing novel cellular and cell-based therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced its participation in three upcoming investor conferences and meetings focused on the biopharma sector. Secretome is scheduled to participate in Guggenheim Securities' Healthcare Private Biopharma Company Virtual 1x1 Day on March 31, 2026, and Piper Sandler's Spring Biopharma Symposium in Boston on April 15-16, 2026. "These invitations reflect growing interest in Secretome's platform and development strategy as we continue advancing STM-01 and our broader pipeline," said Vinny Jindal. "We appreciate the opportunity to engage with investors and industry participants as we work to bring novel therapies forward for patients with serious unmet medical needs." Secretome is advancing STM-01 for Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM), the lead indication for the company's flagship program.Secretome expects to initiate Phase 2 in the second quarter of 2026 and is concurrently preparing for its pivotal Phase 3 program. About Secretome Therapeutics Secretome Therapeutics is a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPCs) for orphan and underserved chronic diseases. Its lead program, STM-01, is being advanced for Duchenne muscular dystrophy-associated cardiomyopathy (DMD-CM), alongside a broader pipeline of nCPC-based therapeutic programs. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding anticipated conference participation, future corporate updates, development timing, and planned clinical and regulatory milestones. Actual results may diXer materially from those expressed or implied by these forward-looking statements due to a variety of risks and uncertainties.
Paragon 28, Inc., a leading orthopedic foot and ankle company, today announced the completion of a Series B financing. The round was co-led by Piper Sandler Merchant Banking, a commercial stage growth equity investment business of Piper Sandler Companies, and MVM Partners, a healthcare growth equity investment firm. The financing also included participation from an existing Series A investor. Read the full article here.